Leaders in Pharmaceutical Business Intelligence (LPBI) Group

UNDATED on 3/8/2016

 

Jennifer Doudna Has Won A CRISPR Gene-Editing Patent

Now, the field is trying to figure out what Caribou Biosciences’ latest patent means.

Originally posted on Feb. 16, 2016, at 6:51 p.m.Updated on Feb. 17, 2016, at 7:52 p.m.

http://www.buzzfeed.com/stephaniemlee/new-crispr-patent#.hkyEyBo2W1

 

CRISPR – genecards.org, UCSC, NM/OK, Caribou BioSciences

Is it possible to go to the dashboard, all posts and click on your Name, you will get the Universe of ~200 articles that you published.

HOW one could search or one needs to visually glance at the title of each — so as to pull a subset of posts that are dedicated to a GENE.

Create an Excel File, place each gene inside and go to Weizmann Institute’s genecards.org and pullout from them respective data on that gene

By so doing we will have LPBI’s Gene Inventory which we could reference in the Drug Discovery process, we do more and more, as we are aggregating all Biologics under the Joint Venture with SBH Sciences, Inc.

In light of :

Leadership in Genomics: VarElect – Variants in Disease and UCSC Genome Technology Center

http://pharmaceuticalintelligence.com/2016/02/17/leadership-in-genomics-varelect-variants-in-disease-and-ucsc-genome-technology-center/

My Questions are:

1. HOW could we take this “to be create Excel File” to be published a PAGE, Password Protected as your Curation, it needs to have a Parent or a Hierarchy of Nesting in the Website architecture

And subject that to your our search into New Medicine, Inc. NM/OK DB for data complementarity compilation?

2. What Foundation Medicine, Now Roche, does have vs. Weizmann Institute’s genecards.org

 http://www.genecards.org/

I read and I visited genecards.org

Most interesting is

http://www.genecards.org/cgi-bin/carddisp.pl?gene=ALB#drugs_compounds

3. Will Weizmann Institute’s genecards.org be interested in New Medicine, Inc., NM/OK DB?

4. I have explored with Foundation Medicine, Now, Roche regarding New Medicine, Inc., NM/OK DB and their reply was that they focus ONLY on Genomics data in Cancer, thus,, no interest in New Medicine, Inc. NM/OK DB, there

5. What is in Weizmann Institute’s genecards.org that is NOT in UC Santa Cruz DBs ?

http://pharmaceuticalintelligence.com/2016/02/17/leadership-in-genomics-varelect-variants-in-disease-and-ucsc-genome-technology-center/

6. If you would take EACH ENTRY in this “to be create Excel File” and supplement it with

6.1 Weizmann Institute’s genecards.org

6.2 UC Santa Cruz DBs

6.3 New Medicine, Inc., NM/OK DB – given this is a GENE in the cancer implication

6.4 A RECORD of the outputs from 6.1, 6.2, 6.3 being created 

7. THEN we could target 6.4 for CRISPR and go to 

http://rna.berkeley.edu/crispr.html

http://rna.berkeley.edu/contact.html

DNA interrogation by the CRISPR RNA-guided endonuclease Cas9

Samuel H. Sternberg, Sy Redding, Martin Jinek, Eric C. Greene & Jennifer A. Doudna Nature 507, 62–67 (06 March 2014) doi:10.1038/nature13011

http://www.nature.com/nature/journal/v507/n7490/full/nature13011.html

and

http://rna.berkeley.edu/translation.html

http://alumni.berkeley.edu/california-magazine/winter-2014-gender-assumptions/cracking-code-jennifer-doudna-and-her-amazing

8. Doudna started her professorship at Yale University in 1994. While the group was able to grow high-quality crystals, they struggled with the phase problem due to unspecific binding of the metal ions. One of her early graduate students and later her husband, Jamie Cate decided to soak the crystals in osmium hexamine to imitate magnesium. Using this strategy, they were able to solve the structure, the second solved folded RNA structure since tRNA.^[9][10] The magnesium ions would cluster at the center of the ribozyme and would serve as a core for RNA folding similar to that of a hydrophobic core of a protein.^[5]

9. In 2015, Doudna gave a TED Talk about the bioethics of using CRISPR. ^[13]

“Jennifer Doudna TED Talk”.

Lastly,

10. Caribou BioSciences

http://cariboubio.com/application-areas/therapeutics

Precision medicines have the ability to transform healthcare and treat a myriad of unmet medical needs. The Caribou technology platform has the ability to generate transformative medicines in multiple different market segments.

Our current therapeutic areas of exploration include anti-microbials, animal health, and therapeutic bioproduction.

Human therapeutics

In 2014, Caribou co-founded Intellia Therapeutics to develop curative medicines utilizing the Caribou CRISPR-Cas9 platform. Rachel Haurwitz, President and Chief Executive Officer of Caribou, is a member of Intellia’s Board of Directors.

Intellia is developing human gene and cell therapies for both ex vivo and in vivo applications using CRISPR-Cas9 gene editing technology. Near-term ex vivo applications include the treatment of blood disorders and cancer. In January 2015, Intellia announced a five-year research and development collaboration with Novartis to accelerate the ex vivo development of new CRISPR-Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs).